Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan.
J Gastroenterol Hepatol. 2013 Feb;28(2):357-64. doi: 10.1111/jgh.12057.
The average age of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) patients has been rising in Japan. We evaluate characteristics of HCV-positive patients who develop HCC in older age to determine an optimal surveillance strategy.
A total of 323 patients with three or more years of follow-up before HCC diagnosis and 323 propensity-matched controls without HCC were studied. HCC patients were classified into four groups according to age at the time of HCC diagnosis: group A (≤ 60 years, n = 36), group B (61-70 years, n = 115), group C (71-80 years, n = 143), and group D (> 80 years, n = 29). Clinical and laboratory data were compared.
Platelet counts were significantly higher in the older groups at HCC diagnosis (P < 0.0001). The rate of platelet counts decline was lower in older groups (P = 0.0107). The average integration value of serum alanine aminotransferase (ALT) in groups A, B, C, and D were 80.9 IU/L, 62.3 IU/L, 59.0 IU/L, and 44.9 IU/L, respectively (P < 0.0001). In older patients (≥ 65 years old), cirrhosis and average integration value of ALT were significantly associated with hepatocarcinogenesis, but platelet count was not.
Elderly HCV-positive patients (≥ 65 years old) with low ALT values developed HCC regardless of their platelet counts. These findings should be taken into account when designing the most suitable HCC surveillance protocol for this population.
在日本,丙型肝炎病毒(HCV)相关肝细胞癌(HCC)患者的平均年龄一直在上升。我们评估了年龄较大的 HCV 阳性患者发生 HCC 的特征,以确定最佳的监测策略。
共研究了 323 例 HCC 诊断前有 3 年以上随访记录的患者和 323 例无 HCC 的倾向匹配对照患者。根据 HCC 诊断时的年龄,将 HCC 患者分为四组:A 组(≤60 岁,n=36)、B 组(61-70 岁,n=115)、C 组(71-80 岁,n=143)和 D 组(>80 岁,n=29)。比较了临床和实验室数据。
在 HCC 诊断时,年龄较大的组血小板计数明显较高(P<0.0001)。年龄较大组血小板计数下降率较低(P=0.0107)。A、B、C 和 D 组血清丙氨酸氨基转移酶(ALT)的平均积分值分别为 80.9IU/L、62.3IU/L、59.0IU/L 和 44.9IU/L(P<0.0001)。在年龄较大的患者(≥65 岁)中,肝硬化和 ALT 的平均积分值与肝癌发生显著相关,而血小板计数则没有。
年龄较大(≥65 岁)的 HCV 阳性患者(无论血小板计数如何),低 ALT 值患者发生 HCC。在为该人群设计最合适的 HCC 监测方案时,应考虑这些发现。